Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development ...

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data for eptinezumab (formerly ALD403), which is in clinical development for the prevention of migraine, will be presented at the upcoming 69th Annual American Academy of Neurology meeting on April 22-28, 2017 in Boston.

• Platform presentation: Randomized, Double-Blind, Placebo-Controlled Trial of ALD403, an Anti-CGRP Peptide Antibody in the Prevention of Chronic MigraineSession: S52, Headache: Clinical Trials and Disease Burden Date: Friday, April 28, 2017 Presenter: Dr. David Dodick Time: 1:24 p.m. Location:  Boston Convention and Exhibition Center

• Poster presentation: Rational Design of a Monoclonal Antibody (mAb) Inhibiting Calcitonin Gene-Related Peptide (CGRP), ALD403, Intended for the Prevention of MigrainePoster: #155 Date: Monday, April 24 Poster Q & A Session: 5:30 p.m. – 7:00 p.m. EDT Location:  Boston Convention and Exhibition Center, Poster Session II

• Poster presentation: 75% Responder Rates Provide Improvement in HIT-6 Scores from Week 4 Through 12 Following a Single Infusion of ALD403, or Placebo Poster: #165 Date: Monday, April 24 Poster Q & A Session: 5:30 p.m. – 7:00 p.m. EDT Location: Boston Convention and Exhibition Center, Poster Session II

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.

Media Contacts:
David Schull or Victoria Meissner
Russo Partners, LLC
[phone]
[phone]
[e-mail]
[e-mail]

Investor Relations Contact:
David Walsey
Alder BioPharmaceuticals Inc.
[phone]
[e-mail]